Trial Profile
Glucose Optimisation With Angiotensin II Antagonist Losartan in Patients With Hypertension and Other Risk Factors for Metabolic Syndrome (GOAAL).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Losartan (Primary) ; Amlodipine
- Indications Essential hypertension; Metabolic syndrome
- Focus Pharmacodynamics
- Acronyms GOAAL
- 11 May 2010 New trial record